

Special Issue

Tumor Microenvironment and Pancreatic Cancer

Message from the Guest Editor

We are pleased to invite you to contribute to the Special Issue of *Cancers* titled “Tumor Microenvironment and Pancreatic Cancer”, edited by Dr. Ijichi. Pancreatic cancer is increasing in prevalence, and is one of the most lethal malignancies, with a 5 year survival of around 9%. The most common type, pancreatic ductal adenocarcinoma (PDAC), is histologically characterized by an abundant stromal component with marked fibrosis and hypovascularity; this tumor microenvironment appears to be highly involved in the pathological condition as well as the catastrophic prognosis. Recently, diversity and heterogeneity in the tumor microenvironment of PDAC are attracting attention. Therefore a more detailed understanding of the complicated microenvironment might be required in order to advance efforts in controlling and conquering PDAC. Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: pathogenesis, early diagnosis, potential therapeutic strategy, therapeutic resistance, and biomarkers in basic, clinical, and translational research, related with tumor microenvironment of PDAC.

Guest Editor

Dr. Hideaki Ijichi

Faculty of Medicine, University of Tokyo, Tokyo, Japan

Deadline for manuscript submissions

closed (20 January 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4

CiteScore 8.8

Indexed in PubMed



mdpi.com/si/95209

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](http://mdpi.com/journal/cancers)

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

